ESMO PUBLIC POLICY

Shaping health policy globally to support medical oncologists and the patients they serve.

esmo.org
ESMO Public Policy Committee

The ESMO Public Policy Committee represents the voice of medical oncology in global, regional and national policy-making, aiming to ensure that our members’ priorities are reflected in health policies across the world.

publicpolicy@esmo.org

Patient Advocates Working Group - working with patients, for patients

Our Patient Advocates Working Group supports the work of the Public Policy Committee to deliver policy solutions that optimise patient care, improve cancer-specific information and education, and strengthen both patient autonomy and rights.

Cancer Medicines Committee

Our Cancer Medicines Committee works to address the topic of access to medicines at the European and global policy levels to ensure that all patients have access to the medicines they need, when they need them.
Sharing our expertise with policy makers to help deliver Europe’s Beating Cancer Plan

Preventing Cancer

- Lowering the incidence of cancer through legislative changes to occupational exposure limits for asbestos, a highly dangerous carcinogenic.
- Preventing lung and breast cancer cases in Europe through our efforts to tighten EU limits on air pollution.
- Countering the influence of ‘big tobacco’ to reduce preventable cancer cases and protect public health.
- Promoting policies which boost vaccination coverage against cancer-causing viruses.
Strengthening the Research Environment

- Ensure that existing legislation like the In Vitro Diagnostic Medical Devices Regulation and the Clinical Trials Regulation facilitate rather than hinder the dynamism of the EU’s oncological research ecosystem.
- Delivering a European Health Data Space that boosts oncology research and the development of innovative treatments for patients with cancer.
- Securing cancer as a priority in the upcoming 10th EU Framework Programme.

Improving Access to Medicines & Treatment

- Supporting the implementation of pharmaceutical legislation to improve the availability, accessibility and affordability of innovative medicines for patients with cancer.
- Informing Health Technology Assessment processes to improve patient accessibility to groundbreaking cancer treatments.
Working with international partners to shape global health policy

World Health Organization (WHO)

• ESMO is a non-state actor (NSA) in official relations with the WHO since 2013 and works with its secretariat and member states towards:

  » The delivery of universal health coverage to ensure the continued and timely access to affordable, essential health services;

  » Optimising the oncology workforce through improved education, training, retention and working conditions;

  » Ensuring that global and national health emergency and pandemic preparedness plans address the needs of patients with cancer.
**The International Agency for Research on Cancer (IARC)**

- ESMO has partnered with IARC - the WHO’s specialised agency on cancer - to develop, since 2020, its World Cancer Report Updates learning platform and promote research into prevention to help reduce the global burden of cancer.

**United Nations’ Economic and Social Council (ECOSOC)**

- ESMO’s special consultative status - the highest rank granted by the UN to non-governmental organisations, and awarded to ESMO in 2020 - with the ECOSOC provides us with the opportunity to work with the UN and its members to help tackle the global scourge of cancer through the delivery of Sustainable Development Goals 3.4 “by 2030, to reduce by one third premature mortality from NCDs through prevention and treatment”, and 3.8 “Achieve Universal Health Coverage”.

Please do get in touch should you have questions concerning ESMO’s public policy work or if you want to discuss how we could help tackle the challenges facing medical oncologists in your country of employment or origin.

publicpolicy@esmo.org